Hematology Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hematology Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Myeloma
Multiple myeloma clinical trial closes early
April 16th, 2007
Mayo Clinic Cancer Center announced that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone. The study led by the Eastern Cooperative Oncology Group (ECOG) and supported by the National Cancer Institute compared combination treatment of oral medications lenalidomide and either high- or low-dose dexamethasone in 445 patients with newly-diagnosed myeloma. Lenalidomide plus high-dose dexamethasone had a one-year survival rate of 86 percent. The comparative therapy using low-dose dexamethasone showed a significantly higher 96.5 percent...
Source: Hematology Week (2007-04-16)
|
